Timothy Sullivan Overview

  • Primary Position
  • Chief Financial...

  • Primary Industry
  • Healthcare

  • Active Board Seats
  • 1

  • Med. Deal Size

  • Med. Valuation

Timothy Sullivan General Information

Biography

Mr. Timothy Sullivan serves as Chief Financial Officer at Apellis. He serves as a Board Member at Allysta. He has served as our chief financial officer since October 2017. From January 2014 to October 2017, he served as a Partner at Aju IB Investment, a venture capital firm, at which he led the firm's investments in life sciences companies. Before joining Aju IB Investment, from December 2011 to January 2014, he was Managing Director and Head of life sciences investment banking at RBS Citizens. He was an observer on the board of directors from November 2014 until October 2017. He has previously served as a director of G1 Therapeutics and Molecular Templates. He received his MBA degree from the Columbia Business School and his BA degree in biology from Harvard University.

Contact Information

Primary Position
Chief Financial Officer, Finance & Treasurer, Finance, Apellis Pharmaceuticals
Education
Columbia Business School, MBA (Master of Business Administration)
Harvard University, BA (Bachelor of Arts)
Gender
Male
Total Investments
Exits
Phone
+1 (502)
Address
  • 6400 Westwind Way
  • Suite A
  • Crestwood, KY 40014
  • United States
+1 (502)

Timothy Sullivan Positions (1)

Firm name Firm type Title Location Industry Since
Apellis Pharmaceuticals Company Chief Financial Officer, Finance & Treasurer, Finance Waltham, MA Drug Discovery

Timothy Sullivan Board Seats (1)

Company Industry Ownership Status Financing Status Location Since
Allysta Drug Discovery Privately Held (backing) Venture Capital-Backed Bellevue, WA

Timothy Sullivan Lead Partner on Deals (2)

Timothy Sullivan has been the lead partner on 2 deals. Their latest deal was with Atea Pharmaceuticals, a drug discovery company. The deal was made for on 17-Sep-2014.

Company Deal Date Deal Type Deal Size Deal Status Industry Location
Atea Pharmaceuticals 17-Sep-2014 Early Stage VC (Series A) Completed Drug Discovery Boston, MA
Molecular Templates 15-Sep-2014 Completed Biotechnology Austin, TX

Timothy Sullivan Network (57)

Board Members (33)

Name Company Representing Location From
Stephen Howard Molecular Templates Self Austin, TX
Christy Shaffer Ph.D G1 Therapeutics Hatteras Venture Partners Durham, NC
Molecular Templates Self Austin, TX
Molecular Templates Self Austin, TX
Allysta Morningside Group Bellevue, WA

Portfolio Executives (24)

Name Company Role Deal date Location
Jean-Pierre Sommadossi Ph.D Atea Pharmaceuticals Chief Executive Officer & Chairman 17-Sep-2014 Boston, MA
Janet Hammond Ph.D Atea Pharmaceuticals Executive 17-Sep-2014 Boston, MA
Atea Pharmaceuticals Executive 17-Sep-2014 Boston, MA
Atea Pharmaceuticals Chief Financial Officer, Finance & Executive Vice President 17-Sep-2014 Boston, MA
Atea Pharmaceuticals Interim Chief Financial Officer 17-Sep-2014 Boston, MA

Timothy Sullivan Affiliated Funds (1)

Fund Investor Fund Type Status Vintage Size Dry Powder IRR IRR Quartile
IBK-AJU Star Seekers No.1 Private Equity Fund AJU IB Investment Buyout Closed 2012

Timothy Sullivan FAQs

  • Who is Timothy Sullivan?

    Mr. Timothy Sullivan serves as Chief Financial Officer at Apellis.

  • How much does Timothy Sullivan typically invest?

    Timothy Sullivan's median deal size is .

  • What is Timothy Sullivan’s main position?

    Timothy Sullivan’s primary position is Chief Financial Officer, Finance & Treasurer, Finance.

  • How many active board seats does Timothy Sullivan hold?

    Timothy Sullivan holds a board seat in Allysta.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »